Leukaemia Trial, Recruiting NCT07588360 Sponsor: Fujian Medical University Union Hospital Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT07588360
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 14 and 60 years old, of any gender.
  • People who have a type of blood cancer called AML that is considered intermediate or high risk, and whose cancer is in a first complete remission (meaning no signs of the cancer are currently detectable).
  • People whose AML is in a second or later complete remission.
  • People whose AML has come back or has not responded to treatment.
  • People with low-risk AML who meet specific conditions related to cancer markers not reducing enough after treatment, or showing signs of returning at a molecular level (confirm with trial site for exact details).
  • People with a type of blood cancer called MDS that is rated as intermediate-2 or high risk using a standard medical scoring system called the IPSS.
  • People who are in generally good enough health to undergo a stem cell transplant procedure.
  • People who are willing and able to sign a consent form and attend the required follow-up visits and tests.

Who may not be able to join:

  • People who have previously had a stem cell transplant of any kind.
  • People who have previously had a specific type of stem cell transplant where certain immune cells were removed before transplant (confirm with trial site).
  • People whose expected survival after the transplant is less than one month.
  • People with serious problems affecting the liver, kidneys, heart, or lungs.
  • People who currently have a severe, uncontrolled infection such as a serious lung infection, blood infection, or other widespread infection in the body.
  • People who have had a severe allergic reaction to certain medications used in the study, including cyclophosphamide or a medicine called anti-thymocyte globulin (ATG).
  • People with a serious mental health condition or significant cognitive difficulties that would make it hard to follow the study treatment plan and attend follow-up.
  • People who are pregnant or currently breastfeeding.
  • People who have another type of cancer in a different part of the body at the same time.
  • People with any other medical condition that the treating doctors consider makes participation in the trial unsuitable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 13365910189

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fujian Medical University Union Hospital
Registry
ClinicalTrials.gov
Start date
20 October 2025
Est. completion
20 October 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov